

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number  
WO 00/72788 A1

(51) International Patent Classification<sup>7</sup>: A61F 9/007 (74) Agents: BRAINARD, Charles, R. et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).

(21) International Application Number: PCT/US00/15200 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 2 June 2000 (02.06.2000) (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 09/324,694 2 June 1999 (02.06.1999) US

(71) Applicant (for all designated States except BB, US): OPTONOL LTD. [IL/IL]; Kiryat Hatikshore, 90850 Neve Ilan (IL).

(71) Applicant (for BB only): WERNER, Mary, C. [US/US]; 0-155 Blue Hill Avenue, Fair Lawn, NJ 07410 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): YARON, Ira [IL/IL]; 215 Har Adar, 93836 (IL). YARDEN, Orit [IL/IL]; 22 Rahavat Ilan, 54056 Givat Shmuel (IL).


Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FLOW CONTROL DEVICE, INTRODUCER AND METHOD OF IMPLANTING

WO 00/72788 A1



(57) Abstract: An implant having a tube for permitting fluid flow has an outer flange at the outlet end and a retention projection near the inlet end. The retention projection acts as a hook engaging the inside surface of the tissue, causing the implant to stay implanted in the tissue. An implant may also be provided with a mechanism for temporary occlusion, in whole or in part, of the flow passage. Thus, the tube passage may be filled, partially or wholly, with absorbable material and/or a plurality of withdrawable or advanceable flow controlling strands.

## FLOW CONTROL DEVICE, INTRODUCER AND METHOD OF IMPLANTING

## FIELD OF THE INVENTION

The invention relates generally to medical implants used to regulate the flow of fluids within the body. The invention may be applied, for example, to 5 ophthalmic implants for treatment of glaucoma. The invention also relates to delivery devices for implanting such implants, to methods of implanting such implants, and to methods of manufacturing such implants.

## BACKGROUND OF THE INVENTION

10 Medical implants used to regulate the flow of fluids within the human body are known and used. One application for the use of such implants is in the treatment of glaucoma. Typical ophthalmic implants utilize drainage tubes for the release of aqueous humor from the eye to 15 relieve the intraocular pressure (IOP).

Several disadvantages have at times been associated with prior implants. For example, implants using valve mechanisms to regulate fluid flow have risked malfunction due to defects in and/or failure of such valve 20 mechanisms. Depending on such factors as the site of implantation, some implants have tended to clog while in use due to tissue covering the inlet end or the outlet end of the drainage tube. In addition, prior implants at times have required insertion operations that are complicated,

costly, and time-consuming, for example requiring suturing of the implant once it is in place.

**PATENTS AND APPLICATIONS INCORPORATED BY REFERENCE**

The assignee of this patent application is also

5 the assignee of other patents and patent applications describing and illustrating implants directed at overcoming some of the drawbacks associated with prior implants, as well as delivery devices for such implants, methods of using such implants, and methods of manufacturing such implants.

10 For example, implants, delivery devices, methods of use, and methods of manufacturing are described and illustrated in United States Patent No. 5,868,697 and United States Patent No. 5,702,414, both of which are owned by the assignee of this application, and both of which are hereby

15 expressly incorporated by reference into this application.

Further examples of such implants, delivery devices, methods of use, and methods of manufacturing are also described and illustrated in United States Patent Application No. 08/975,386, filed November 20, 1997, which

20 is also owned by the assignee of this application, and which is also hereby expressly incorporated by reference into this application.

#### SUMMARY OF THE INVENTION

One object of the invention is to provide a flow regulating implant and an associated delivery device that enable the implant to be inserted in a relatively simple and 5 efficient procedure.

In one embodiment in accordance with the invention, an implant having a tube for permitting fluid flow has an outer flange at the outlet end and one or more retention projections near the inlet end. An introducer or 10 delivery device for implanting the implant has a central bore for accommodating the implant during the implantation procedure. The implant and delivery device are designed so that when the implant is loaded in the delivery device, the retention projection or projections of the implant protrude 15 from the delivery device to act as a hook or hooks during the procedure.

In accordance with a method of using the implant and delivery device according to an embodiment of the invention, the implant is loaded in the delivery device with 20 the retention projection protruding from the delivery device. The delivery device and implant then penetrate the tissue through which drainage is desired, for example, the sclera of an eye. Once the retention projection has fully penetrated through the tissue, the delivery device is 25 withdrawn. The retention projection acts as a hook engaging the inside surface of the tissue, causing the implant to

stay implanted in the tissue when the delivery device is withdrawn.

The retention projection may be made, for example, of an elastic material, so that it is able to be flexed 5 inward against the tube of the implant during penetration through the tissue. Alternatively, the retention projection may be designed to lie initially relatively flat against the tube for easier penetration and to prevent tearing of the tissue, with a mechanism for extending the retention 10 projection outwardly when the implant is implanted.

Another object of the invention is to provide a simple and efficient method of manufacturing a flow regulating implant. In a method for manufacturing an implant according to an embodiment of the invention, the 15 device may be molded out of a suitable material, for example, silicone. To provide the tube passage of the implant, a thin wire may be used during the molding process. The implant alternatively may be constructed out of stainless steel or any other suitable material.

20 A further object of the invention is to provide a flow regulating implant with beneficial flow characteristics. Thus, the implant may have various mechanisms for changing the configuration of the flow path. For example, a flow controlling rod or other obstruction may 25 be placed in the tube passage for changing the dimensions within the tube passage. This rod or obstruction may be

temporary. For example, it may be made of absorbable (biodegradable) material that is eroded and absorbed. Alternatively, it may be constructed in such a way that it may be removed from the tube passage or advanced into the 5 tube passage at a period of time after implantation. For example, one or more strands, such as sutures, may be placed in the tube passage and withdrawn or advanced by a physician as desired at a later time or times.

An implant according to the invention has other 10 applications aside from the field of intraocular implants. For example, the implant may be used for drainage of a hydrocele sac, regulating flow between the hydrocele sac and the subcutaneous scrotum. Persons of ordinary skill in the art will appreciate that other applications of an implant in 15 accordance with the invention are possible, as are various modifications of the embodiments described herein, without departing from the scope of the invention as defined in the claims.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 Figure 1A is a side view of a first embodiment of a drainage implant;

Figure 1B is an end view of the drainage implant shown in Figure 1A;

Figures 2A through 2C illustrate a delivery device and insertion of the drainage implant of Figure 1A into desired tissue, with Figure 2A showing the delivery device and implant before insertion,  
5 Figure 2B showing the delivery device and implant being placed through the tissue, and Figure 2C showing the inserted implant after the delivery device has been withdrawn;

10 Figure 3A is a side view of a second embodiment of a drainage implant;

Figure 3B is an end view of the drainage implant shown in Figure 3A;

Figure 3C is a cross-sectional view taken along the plane identified by the line 3C--3C in Figure 3A;

15 Figure 4A is a side view of a third embodiment of a drainage implant;

Figure 4B is an end view of the drainage implant shown in Figure 4A;

20 Figure 5 illustrates a second embodiment of a delivery device with an implant inserted in the delivery

device and with the procedure at a stage corresponding to that in Figure 2B;

5 Figure 6 illustrates an intraocular implant according to the invention with a flow controlling plug made of absorbable material in the tube passage;

Figures 7A through 7D illustrate four variations of cross-sections for a flow controlling plug;

10 Figure 8 illustrates an intraocular implant according to the invention with a flow controlling plug made of absorbable material in the tube passage and with side holes partially occluded by plugs made of absorbable material;

15 Figure 9 illustrates an intraocular implant according to the invention with flow controlling strands in the tube passage;

Figure 10 illustrates an end view of an intraocular implant with flow controlling strands in the tube passage;

20 Figure 11 illustrates an intraocular implant according to the invention with a knotted flow controlling strand in the tube passage; and

Figure 12 illustrates an alternative construction of a flow controlling strand.

#### DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

Figures 1A and 1B show a side view and end view, 5 respectively, of a first embodiment of a drainage implant 10 in accordance with the invention. The implant 10 has a tube 12 having a tube passage 14 for permitting fluid flow between an inlet end of the implant and an outlet end of the implant. One or more side holes 16 may be provided around 10 the circumference of the tube 12 near the inlet end, allowing access for fluid flow into the tube passage 14.

The implant 10 has an outer flange 18 at the outlet end and a retention projection 20 near the inlet end. The plane of the outer flange 18 may form an angle with the 15 tube 12, with the angle selected to correspond to the angle between the surface of the tissue into which the implant 10 is to be inserted and the axis of insertion of the tube 12 of the implant 10.

Figures 2A through 2C illustrate an introducer or 20 delivery device 30 for implanting the implant 10 and the method of implanting the implant 10 with that delivery device 30. The delivery device 30 has handle 32 and a tube 34 having a central bore 36 for accommodating the implant 10 during the implantation procedure. The delivery device 30 25 has a beveled tip 38 to allow penetration of the tissue 50

into which the implant is to be inserted. In an alternative embodiment, the implant itself penetrates the tissue by its beveled tip at the inlet end.

An opening 40 is provided in the wall of the tube 5 34 of the delivery device 30. In this illustrated embodiment, the opening 40 allows both the retention projection 20 and the outer flange 18 to protrude beyond the wall of the tube 34 when the implant 10 is loaded in the delivery device 30. Because it projects beyond the wall of 10 the tube 34, the retention projection 20 of the implant 10 can act as a hook during the implantation procedure.

As can be seen in Figure 1B, the flange 18 of the implant 10 has notches or grooves 19 on either side. These notches or grooves 19 correspond approximately to the width 15 of the wall of the tube 34 of the delivery device 30 and accommodate the wall of the tube 34 of the delivery device 30 when the implant 10 is loaded in the delivery device 30. The notches or grooves 19 may take any suitable shape. Alternatively, the flange 18 may have a continuous width, 20 with no notches or grooves, with the width of the flange 18 being slightly narrower than the diameter of the tube 12 of the implant 10. Further variations of the configuration of the flange 18 are possible.

To use the implant 10 and delivery device 30, the 25 implant 10 is loaded in the delivery device 30 with the retention projection 20 protruding from the delivery device,

as shown in Figure 2A. The delivery device 30, with the implant loaded inside, is then pressed through the tissue 50 through which drainage is desired, for example, the sclera of an eye. Figure 2B illustrates the delivery device 30 5 pressed through the tissue 50.

To facilitate introduction of the delivery device 30 and/or implant 10 into the tissue 50, the delivery device 30 may be oriented such that the beveled tip 38 forms a sharper angle with the tissue 50. Thus, for example, the 10 delivery device as shown in Figure 2A may be rotated 180 degrees, i.e., with the retention projection 20 facing upward. In the case of an implant 10 being placed into the limbal sclera of an eye, this corresponds to the retention projection 20 being on the opposite side of the tube 12 from 15 the iris. When the delivery device 30 and implant 10 are suitably through the tissue 50, they may be rotated to align the implant 10 properly in the tissue 50, with the flange 18 and retention projection 20 oriented as desired with respect to the tissue 50.

20 Once the retention projection 20 has fully penetrated through the tissue 50, the delivery device 30 is withdrawn. The retention projection 20 acts as a hook engaging the inside surface of the tissue 50, causing the implant 10 to stay implanted in the tissue 50 when the 25 delivery device 30 is withdrawn. Figure 2C illustrates the implant 10 implanted in the tissue 50, with the delivery

device 30 withdrawn.

Since the tube 34 of the delivery device 30 is hollow, it may be used to inject fluid or viscoelastic material. Thus, fluid may be injected into the anterior 5 chamber of an eye upon implantation to reduce the risk of hypotony. Similarly, a viscoelastic material may be injected under the conjunctiva to help fill the bleb that exists after implantation.

The implant 10 may be molded out of a suitable 10 material, for example, silicone. To provide the tube passage 14 of the implant 10, a thin wire may be used during the molding process. More than one wire may be used, in order to have more than one tube passage in the implant. The implant alternatively may be constructed out of 15 stainless steel or another suitable material. It may be coated with a suitable anti-fibrosis material, such as heparin.

The retention projection 20 may be formed of the same material as the rest of the implant 10. Alternatively, 20 it may be made of a more flexible material to allow it to be flexed inward against the tube 12 of the implant 10 during penetration through the tissue 50. Alternatively, the retention projection 20 may be designed to lie initially relatively flat against the tube 12 for easier penetration 25 and to prevent tearing of the tissue 50, to be extended outwardly by an expansion mechanism, for example a balloon,

when the implant 10 is implanted.

Figures 3A, 3B and 3C show a side view, end view, and cross-section, respectively, of a second embodiment of a drainage implant 60 in accordance with the invention. Like 5 the implant 10 shown in Figures 1A and 1B, the implant 60 in Figures 3A, 3B, and 3C has a tube 62 having a tube passage 64 and side holes 66 opening into the tube passage 64. The implant 60 also has an outer flange 68 at the outlet end and a retention projection 70 near the inlet end. In this case, 10 the outer flange 68 projects beyond the outer surface of the tube 62 in all directions around the circumference of the tube 62.

Figures 4A and 4B show a side view and end view, respectively, of a third embodiment of a drainage implant 15 80, similar to the implant 60 shown in Figures 3A, 3B, and 3C. The tip 82 of the implant 80 is conical, in contrast to the blunt tip 72 of the implant 60.

In an alternative construction, the implant may be made with a closed end with a slit in it. Fluid can only 20 pass through the device when the pressure rises sufficiently to open the slit. Alternatively, a different portion along the length of the tube passage may be provided with such a construction.

Figure 5 illustrates an alternative embodiment of 25 a delivery device 90 in accordance with the invention. In this embodiment, the opening 92 allows only the retention

projection 84 of the implant to protrude beyond the wall of the tube 94 of the delivery device. The outer flange 86 is accommodated within the central bore 96 of the delivery device 90. In this embodiment, the outer flange 86 must be 5 folded or bent to be accommodated within the central bore 96 of the delivery device 90. The outer flange 86 is resilient, so that when the implant is removed from the delivery device, the outer flange 86 extends to a position relatively coplanar with the outer surface of the tissue 10 into which the implant is inserted.

Similarly, the retention projection 84 may also be constructed to be sufficiently resilient to allow it to be compressed and completely accommodated within the central bore 96 of the delivery device 90. In addition, the 15 delivery device 90 may be constructed with the tube 94 having a continuous outer wall, with no opening 92. To facilitate removal of the implant from the delivery device, a pusher rod or wire may be located within the bore of the delivery device. By advancing the pusher rod or wire within 20 the delivery device against the implant, the physician can force the implant out of the delivery device, thereby allowing the retention projection to expand outwardly to its initial, relaxed position, enabling it to engage the inside surface of the tissue.

25 Various mechanisms may be used, if desired, for giving different flow characteristics to the implant. It

may be desirable to use implants with different flow characteristics for different patients and/or to have an implant in which the flow characteristics may be changed after implantation in a particular patient.

5                   U.S. Patent Application No. 08/975,386, filed November 20, 1997 and incorporated by reference herein, describes and illustrates various mechanisms for assisting in controlling the flow of fluid, e.g. aqueous humor, through an implant. It describes and illustrates the use of  
10 a flow controlling wire or rod in the tube passage of an implant.

The effect of the flow controlling rod or wire is to reduce the cross-sectional area through which the fluid flows for a particular length inside the tube passage of the  
15 implant. Because the flow is a function of the cross-section and length of the lumen through which it passes, the interposition of the flow controlling rod or wire serves to increase the resistance to flow. In an intraocular implant, for example, this assists in reducing  
20 the risk of hypotony.

The configuration and dimensions of the flow controlling rod or wire may be selected in accordance with the flow characteristics that are desired. It may have one or more internal bores or external grooves, any of which may  
25 be helically arranged to increase its length. It may be adjustable, by moving it axially or rotating it, to modify

the flow characteristics. Persons skilled in the art will appreciate that numerous other variations are possible for the configuration of the flow controlling rod or wire.

The flow controlling rod or wire may have its axis 5 aligned parallel with the axis of the tube passage, but other orientations are possible. For example, a flow controlling rod or wire having a diameter slightly smaller than the tube passage may be oriented transverse to the tube passage. The transversely oriented rod or wire will have a 10 short length, corresponding approximately to the diameter of the tube or tube passage. It serves as an obstruction to the flow through the tube passage, altering the flow characteristics. Other obstruction may be placed in the tube passage for achieving similar results.

15 Another mechanism described and illustrated in U.S. Patent Application No. 08/975,386 for assisting in controlling the flow of fluid through an implant is the use of temporary occlusion. By occluding the flow passage of the implant with an absorbable material or with a material 20 that may be removed after implantation, for example by a tool or laser probe, the resistance to flow can be reduced after implantation.

The use of temporary occlusion is advantageous in situations in which flow through the implant is desired to 25 be kept low at implantation, and possibly also for a period of time after implantation. For example, when an implant is

implanted in the eye, the incision in the conjunctiva and/or possible tearing of the sclera around the implant provide potential flow passages for aqueous humor. Thus, to reduce the risk of hypotony, it may be desirable to prevent or 5 reduce flow through the implant upon implantation and for a period thereafter. Once the conjunctiva and/or sclera have healed, the flow through the implant can be increased.

The temporary occlusion need not be limited to any particular part of the flow passage. For example, the side 10 holes and/or the tube passage of the implant may be filled, partially or wholly, with absorbable material. Thus, for example, as shown in Figure 6, a plug 106A of absorbable material may be placed in the tube passage 102 of the implant 100. With an absorbable material that biodegrades 15 by surface erosion, as fluid contacts and flows adjacent to the plug 106A, the material of the plug 106A is absorbed into the fluid, thereby reducing the dimensions of the plug 106A. As the dimensions of the plug 106A are reduced, the resistance to flow through the implant is similarly reduced. 20 Alternatively, an absorbable material that biodegrades by bulk erosion may be used. Absorbable (biodegradable) materials are known and used, and such materials are described, for example, in Middleton & Tipton, "Synthetic Biodegradable Polymers as Medical Devices," Medical Products 25 and Biomaterials, March 1998.

Figure 6 shows the plug 106A only partially

filling the tube passage 102, but it will be appreciated that the plug 106A may completely fill the tube passage 106A. In that case, fluid flow would initially be completely obstructed. Fluid flow begins only after the 5 plug 106A has been sufficiently absorbed to provide a path for fluid to flow out of the implant.

An absorbable plug may be used with any suitable configuration of implant, including implants with flow controlling rods or other flow controlling obstructions.

10 Similarly, an absorbable plug may have any suitable configuration and dimensions, selected in accordance with the flow characteristics that are desired. If desired, more than one absorbable plug may be used.

Some possible cross-sectional shapes for 15 alternative absorbable plugs are shown in Figures 7A through 7D. Absorbable plug 106A has a circular cross-section. Absorbable plug 106B is similar to absorbable plug 106A with the addition of external grooves 108B. Absorbable plug 106C has a flat surface 110C. Absorbable plug 106D has a 20 longitudinal bore 112D. Alternative constructions include combining external grooves and internal bores, changing the number of them, and/or arranging them helically or in any other suitable configuration. The absorbable plug may be in a tapered or other suitable shape. It will be appreciated 25 that the configuration of the absorbable plug will affect the absorption of the absorbable plug, with the areas in

contact with the fluid being absorbed first.

Figure 8 shows the use of an absorbable plug 106A in conjunction with partially occluded side holes 104. Each of the side holes 104 is partially occluded by absorbable 5 plugs 114, each of which has a central bore 116. As with the absorbable plug 106A in the tube passage 102, the absorbable plugs 114 in the side holes 104 may have any suitable configuration, and may be used in conjunction with any configuration of absorbable plug in the tube passage or 10 with no absorbable plug in the tube passage.

Figures 9 through 11 show alternative mechanisms for partial and/or temporary occlusion of the flow passage. In Figure 9, the intraocular implant 120 has a number of flow controlling strands 126 in the tube passage 122. The 15 flow controlling strands 126 serve to alter the flow characteristics through the implant, either partially or wholly obstructing flow through the implant. The number and/or size of the strands may be varied as desired, and the strands may be of any suitable material. For example, 20 ordinary sutures, such as polypropylene sutures, may be used.

At a period of time after implantation, one or more of the flow controlling strands 126 may be withdrawn from the implant (or advanced into the implant). Further 25 strands may be withdrawn (or advanced) at later times. In this manner, the obstruction to flow through the implant can

be altered, at once or over a period of time, after the implantation procedure has taken place.

It will be appreciated that the ability to withdraw or advance one or more strands over time allows the 5 physician to alter the flow characteristics of the implant in accordance with the needs of the patient. For example, at a certain period of time after the implant has been implanted in a patient's eye, the physician can check the intraocular pressure of the eye and determine whether one or 10 more strands should be withdrawn or advanced to increase or reduce flow through the implant. The patient can be checked periodically, and the strands can be left in place, withdrawn or advanced as appropriate over a period of time.

The ability to withdraw strands is useful in the 15 event the implant should become clogged. In such a case, the physician can withdraw one or more strands in order to restore proper flow through the implant.

Figure 10 shows an end view of an implant with a plurality of flow controlling strands 126 in the tube 20 passage 122. It will be appreciated that the strands 126 may be arranged within the tube passage 122 in any suitable manner, and the shape and configuration of the strands 126 are not limited to that shown. For example, the strands may have different cross-sections (e.g., oval, semi-circular, 25 irregular, hollow, etc.) and different sizes. The cross-sectional shapes and dimensions may vary along the length of

a single strand. Each of the strands in a single implant may have different configurations, e.g., different cross-sectional shapes and/or dimensions. With different strands in the implant, the physician can selectively withdraw (or 5 advance) the appropriate strand or strands in accordance with the desired flow characteristics. For example, if a small increase in flow is desired, a strand with a small cross-section can be withdrawn, and if a larger increase in flow is desired, a strand with a larger cross-section can be 10 withdrawn.

Figure 11 shows an implant in which a single flow controlling strand 128 having a knot 130 is placed within the tube passage 122. The knot 130 serves to increase the flow obstruction. Alternatively, a plug or other 15 obstruction may be attached to the strand 128, and more than one strand 128 with a knot, plug or other attached obstruction may be used. Similar to the use of strands of different shapes and/or sizes, strands may be used having knots or plugs of different shapes and/or sizes, allowing 20 selective withdrawal or advancement of the appropriate strand or strands in accordance with the desired flow characteristics.

Figure 12 shows an alternate construction of a flow controlling strand 132 in which the cross-sectional 25 size of the strand varies along its length. The illustrated strand 132 has three different sections. Section 138 on the

end of the strand has the smallest diameter, the adjacent section 136 has a slightly larger diameter, and the remainder 134 of the strand has an even larger diameter. The remainder 134 of the strand may be sized to correspond 5 to the diameter of the tube passage, with the sections 136 and 138 being incrementally smaller. Thus, with a tube passage having a diameter, for example, of 100 microns, the strand may also have a diameter of 100 microns, with incremental steps down to, for example, 20 microns. Of course, other dimensions may be used, and the remainder 134 of the strand need not have the same size as the tube 10 passage. In the initial positioning, the strand 132 is located in the tube passage of the implant with the section 138 near the inlet end and with part of the section 134 located within the tube passage near the outlet end. When 15 it is desired to increase the flow in the implant, the strand 132 may be partially withdrawn such that only section 134 comes out of the tube passage. Thus, the obstruction within the tube passage is decreased, thereby increasing the 20 flow. Later, if desired, the other sections may be successively withdrawn. Alternatively, the strand may be further advanced into the tube passage to further constrict flow.

Variations of the strand shown in Figure 12 are 25 possible, with the sections being aligned along the strand in any desired pattern. The concept of a single strand

which may be partially withdrawn or advanced in successive increments to vary the flow in steps may additionally or alternatively be achieved by using knots or plugs of different shapes and/or sizes along the length of a strand.

5       A flow controlling strand in accordance with the invention may be completely separate from the implant and inserted into the implant some period of time after implantation, or the strand may be partially in the implant upon implantation, with the option of advancing it further  
10      into the implant at a later time.

      An implant having withdrawable (and/or advanceable) flow controlling strands may be implanted using a delivery device 30 as shown in Figure 2A. In such a case, the strands that extend out of the outlet end of the implant  
15      may be accommodated in the central bore 36 of the delivery device 30. Alternatively, with a suitably sized opening 40 in the wall of the tube 34 of the delivery device 30, the strands may pass outside of the delivery device 30.

      When the implant is implanted in an eye, the flow  
20      controlling strands can be oriented to extend under the conjunctiva away from the implant. The strands used may be long enough to extend out of the implant beyond the slit made in the conjunctiva for inserting the implant. In this case, after implanting the implant, the physician can tuck  
25      the loose ends of the strands under the conjunctiva to extend away from the slit. When it is desired to withdraw

one or more of the strands, a small slit can be made in the conjunctiva near the ends of the strands, and the strands can be pulled through that slit. Because these ends are remote from the implant and the prior slit made in the 5 conjunctiva, the potential trauma to the eye is reduced.

To fix the strands in place and facilitate later access to them, the loose ends may be sutured to the adjacent tissue, e.g., the sclera. This may be done either with additional sutures or with the strands themselves. In 10 the latter case, suturing needles may be attached to the loose ends of the strands to facilitate suturing of the strands after implantation of the implant.

It will be appreciated that various features of the above-described embodiments may be combined as desired. 15 For example, the flow controlling strands may be made of absorbable material, leaving the option of having a physician physically withdraw the strands or allowing them to be absorbed. Additionally or alternatively, plugs or other obstructions secured to the strands may be made of 20 absorbable material. Different strands, plugs or obstructions may be made from materials with different rates of absorption, and/or they may be made from a combination of materials with different rates of absorption.

As will also be appreciated by persons having 25 ordinary skill in the art, the various embodiments of implants, methods of manufacture, delivery devices, and

methods for implantation described hereinabove are given by way of example only. Various changes, modifications and variations may be applied to the described embodiments without departing from the scope of the invention, defined 5 by the appended claims.

## What is Claimed is:

1. An implant in combination with a delivery device for implanting the implant, wherein the implant comprises a tube and an outwardly extending retention projection, wherein the delivery device comprises a tube having an outside surface and a central bore for accommodating the implant, and wherein the delivery device has an opening in the side of the tube allowing the retention projection to project beyond the outside surface of the tube of the delivery device.  
5
2. An implant and delivery device according to claim 1, wherein the implant is formed of plastic.
3. An implant and delivery device according to claim 1, wherein the retention projection is located at an inlet end of the implant, and wherein the implant further comprises an outer flange located at an outlet end of the implant.  
15
4. An implant and delivery device according to claim 3, wherein the opening in the side of the tube of the delivery device also allows the outer flange of the implant to project beyond the outside surface of the tube of the delivery device.  
20

5. An implant and delivery device according to claim 3, wherein the outer flange of the implant is resilient so that it may be accommodated within the central bore of the tube of the delivery device.
- 5 6. An implant in combination with a delivery device for implanting the implant, wherein the implant comprises a tube having an inlet end and an outlet end and an outwardly extending retention projection, wherein the delivery device comprises a tube having an outside surface, a central bore for accommodating the implant and an opening at one end for allowing the implant to exit the central bore, and wherein the implant is accommodated within the central bore with its inlet end closer to the opening than its outlet end so that the inlet end of the implant exits the central bore of the delivery device before the outlet end.
- 15 7. An implant and delivery device according to claim 6, wherein the implant is formed of plastic.
8. An implant and delivery device according to claim 6, 20 wherein the retention projection is located proximate the inlet end of the implant, and wherein the implant further comprises an outer flange located proximate the outlet end of the implant.

9. An implant and delivery device according to claim 8, wherein the outer flange of the implant is resilient so that it may be accommodated within the central bore of the tube of the delivery device.
- 5 10. An implant and delivery device according to claim 6, wherein the retention projection of the implant is resilient so that it may be accommodated within the central bore of the tube of the delivery device.
- 10 11. A delivery device for use in implanting an implant, wherein the delivery device comprises a tube having an outside surface and a central bore for accommodating the implant, and wherein the delivery device has an opening in the side of the tube allowing a retention projection of the implant to project beyond the outside surface of the tube of the delivery device.
- 15 12. A delivery device according to claim 11, wherein the opening in the side of the tube of the delivery device also allows an outer flange of the implant to project beyond the outside surface of the tube of the delivery device.
- 20 13. A method of implanting an implant, comprising the steps of:

placing the implant in a central bore of a delivery device, said placing step including allowing a retention projection of the implant to project beyond an outer surface of a tube of the delivery device;

5 inserting the delivery device with the implant placed in the delivery device through tissue into which the implant is to be implanted; and

withdrawing the delivery device, leaving the implant implanted in the tissue.

10 14. A method of implanting an implant, comprising the steps of:

placing the implant in a central bore of a delivery device, said placing step including positioning the implant so that the implant is accommodated within the central bore with an inlet end of the implant closer to an opening in the delivery device than an outlet end of the implant;

15 inserting the delivery device with the implant placed in the delivery device through tissue into which the implant is to be implanted; and

20 withdrawing the delivery device, leaving the implant implanted in the tissue.

15. A method of manufacturing a flow control device comprising the steps of:

providing a mold having a cavity with a generally tubular shape;

5 positioning a wire within the mold such that the wire is suspended to extend along a longitudinal axis of the generally tubular shaped cavity;

10 putting a moldable material into the mold; and allowing the moldable material to harden such that it hardens in the generally tubular shape of the mold, with a longitudinal tube passage formed in the hardened material on account of the wire positioned in the mold.

16. An implant for regulating fluid flow comprising:

15 a tube comprising an inlet end, an outlet end, and a tube passage extending between the inlet end and the outlet end for permitting fluid to flow through the tube passage; and

20 absorbable material located within the tube passage, wherein initially the absorbable material serves to partially or wholly obstruct flow through the tube passage and wherein the absorbable material erodes as it contacts fluid such that the obstruction of flow through the tube passage is reduced over time.

17. An implant according to claim 16, wherein initially the absorbable material substantially fills the tube passage so as to prevent flow through the tube passage.

18. An implant according to claim 16, wherein initially the absorbable material partially fills the tube passage so as to allow partial flow through the tube passage.
19. An implant for regulating fluid flow comprising:
  - 5 a tube comprising an inlet end, an outlet end, and a tube passage extending between the inlet end and the outlet end for permitting fluid to flow through the tube passage; and
  - 10 one or more flow controlling strands located within the tube passage, wherein initially the one or more flow controlling strands serve to partially or wholly obstruct flow through the tube passage and wherein at least one flow controlling strand may be displaced with respect to the tube passage to change
  - 15 the obstruction of flow through the tube passage.
20. An implant according to claim 19, wherein initially the one or more flow controlling strands substantially fill the tube passage so as to prevent flow through the tube passage.
21. An implant according to claim 19, wherein initially the one or more flow controlling strands partially fill the tube passage so as to allow partial flow through the tube passage.

22. An implant according to claim 19 further comprising a plug attached to one or more of said flow controlling strands.
23. An implant according to claim 19 wherein one or more of  
5 said flow controlling strands has a knot in it.
24. An implant according to claim 19, wherein at least one flow controlling strand may be withdrawn from the tube passage to reduce the obstruction of flow through the tube passage.
- 10 25. An implant according to claim 24, wherein at least one flow controlling strand may be completely withdrawn from the tube passage to reduce the obstruction of flow through the tube passage.
- 15 26. An implant according to claim 24, wherein at least one flow controlling strand may be partially withdrawn from the tube passage to reduce the obstruction of flow through the tube passage.
- 20 27. An implant according to claim 19, wherein at least one flow controlling strand may be advanced within the tube passage to increase the obstruction of flow through the tube passage.

28. An implant according to claim 19 comprising at least two strands.
29. An implant according to claim 28, wherein two of the strands have different cross-sectional dimensions.
- 5 30. An implant according to claim 28, wherein each of at least two strands has a plug attached to it, with the plugs on the at least two strands having different cross-sectional dimensions.
31. An implant according to claim 28, wherein each of at 10 least two strands has a knot in it, with the knots in the at least two strands having different dimensions.
32. An implant according to claim 19 wherein at least one flow controlling strand has different areas along its length with different cross-sectional dimensions.
- 15 33. An implant according to claim 19 wherein at least one flow controlling strand is made of absorbable material.
34. An implant for regulating fluid flow comprising:  
a tube comprising an inlet end, an outlet end, and  
a tube passage extending between the inlet end and the  
20 outlet end for permitting fluid to flow through the

tube passage; and

means for temporarily obstructing, in whole or in part, fluid flow through the tube passage.

35. An implant according to claim 34 wherein the means for temporarily obstructing, in whole or in part, fluid flow through the tube passage comprises absorbable material located in the tube passage.
  
36. An implant according to claim 34 wherein the means for temporarily obstructing, in whole or in part, fluid flow through the tube passage comprises at least one flow controlling strand located in the tube passage.

1/4




Fig. 1a




Fig. 1b




Fig. 2a




Fig. 2b




Fig. 2c

2/4




Fig. 3a




Fig. 3b



Fig. 3c




Fig. 4a




Fig. 4b




Fig. 5

3/4




Fig. 6




Fig. 7a




Fig. 7b




Fig. 7c




Fig. 7d




Fig. 8

4/4




Fig. 9




Fig. 10




Fig. 12




Fig. 11

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/15200

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61F9/007		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61F A61M		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 300 020 A (L ESPERANCE JR FRANCIS A) 5 April 1994 (1994-04-05) figures 1-4 column 3, line 3 - line 48 column 3, line 64 -column 4, line 9 column 7, line 41 - line 68 claims 1-3,8-11  ---  -/--	15-18, 34-36
A		1,6,11, 19
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
* Special categories of cited documents :  "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search report	
26 September 2000	05/10/2000	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3046		Authorized officer  Mary, C

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/15200

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 99 26567 A (OPTONOL LTD ; YARDEN ORIT (IL); YARON IRA (IL); WERNER MARY C (US)) 3 June 1999 (1999-06-03) cited in the application figures 1,5-10,18-29 page 18, line 25 -page 19, line 18 page 21, line 12 - line 24 page 24, line 13 - line 19 page 28, line 4 - line 21 page 31, line 15 - line 28</p>	15-22, 24-27, 32-36
Y A	---	1,6,12 1-12,23, 28-31
X	<p>FR 2 757 068 A (JUSSMANN ALBERTO) 19 June 1998 (1998-06-19) figures 1-4 page 7, line 13 - line 34</p>	11
Y	---	1,6,12
A	<p>US 5 358 492 A (FEIBUS MIRIAM H) 25 October 1994 (1994-10-25)</p> <p>figures 12,13 column 6, line 15 - line 30</p>	1,6,11, 15,16, 19-34
A	<p>US 5 800 376 A (VASKELIS PAUL S ET AL) 1 September 1998 (1998-09-01)</p> <p>figure 2 claims 1-4</p>	1,6,11, 15,16, 19,34
	-----	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/15200

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5300020	A	05-04-1994	NONE		
WO 9926567	A	03-06-1999	AU 1419199 A	15-06-1999	
			EP 1032334 A	06-09-2000	
FR 2757068	A	19-06-1998	NONE		
US 5358492	A	25-10-1994	US 5180375 A	19-01-1993	
			AU 5295793 A	19-07-1994	
			EP 0693945 A	31-01-1996	
			WO 9414486 A	07-07-1994	
			WO 9219292 A	12-11-1992	
US 5800376	A	01-09-1998	US 5662600 A	02-09-1997	
			AU 6863896 A	17-04-1997	
			WO 9711726 A	03-04-1997	

